Evaluation of fipronil spot-on in the treatment of flea allergic dermatitis in dogs.

The purpose of this study was to evaluate the effectiveness of treatment with 10 per cent fipronil solution for controlling signs of flea allergic dermatitis in dogs under field conditions. Thirty-one client-owned dogs with flea allergic dermatitis were treated with three monthly applications of 10 per cent fipronil solution. Flea counts and pruritus were significantly reduced at all post-treatment visits. At the final visit, on day 90, flea counts were reduced by 98 per cent, and pruritus was reduced or eliminated in 84 per cent of the study dogs. Dermatological lesion scores for erythema, crusts, scales and papules were also significantly improved by the final visit. The overall assessment of efficacy on day 90 was 'excellent' to 'good' for 87 per cent of the study dogs. The results demonstrate that treatment with monthly topical applications of 10 per cent fipronil solution is effective in reducing the prevalence and severity of signs of flea allergic dermatitis in dogs.

Efficacy of a long-acting formulation of ivermectin against Psoroptes ovis (Hering, 1838) on cattle.

A study was conducted in cattle experimentally infested with Psoroptes ovis to compare the prophylactic control against P. ovis provided by a long-acting injectable formulation of ivermectin to that of a commercially available injectable formulation of doramectin. Thirty Holstein steers were used. Animals were allocated by restricted randomization based on Day 0 body weight, forming six replicates of five animals each. Within each replicate, one animal was randomly allocated to one of the following treatment groups, with ivermectin and doramectin administered subcutaneously where indicated: (1) untreated controls; (2) ivermectin long-acting injectable (LAI) 630 mcg/kg, 56 days before challenge; (3) ivermectin LAI 630 mcg/kg, 42 days before challenge; (4) ivermectin LAI 630 mcg/kg, 35 days before challenge; or (5) doramectin 200 mcg/kg, 35 days before challenge. Animals were housed in individual pens 1 week prior to treatment. All animals were experimentally infested with P. ovis mites in the area between the shoulders, on the same day. Live mites were counted in scrapings from mange lesions at 2 sites on each animal 14, 21 and 28 days after challenge. Live mites were found in 33, 67 and 83% of the untreated controls on each respective evaluation. No P. ovis mites were found in steers treated with ivermectin LAI. Those animals showed lower (P < 0.05) mite counts than untreated controls on evaluations conducted 21 and 28 days after challenge. These results indicate that the ivermectin long-acting injectable formulation prevents induced infestations by P. ovis for at least 56 days after treatment. Doramectin injectable formulation, used at 200 mcg/kg, did not have a prophylactic effect 35 days after treatment.

Evaluation of the effect of simulated rainfall on the efficacy of Ivomec Pour-On against Cooperia spp. infection in cattle.

Four controlled studies, one each in Australia, Germany, the United Kingdom, and the United States, involving 30 calves each were conducted to evaluate the effect of simulated rainfall on the efficacy of Ivomec Pour-On against infections of Cooperia spp. At 3 weeks before treatment the calves were infected orally with third-stage larvae of Cooperia spp. In each study a recent, locally derived field isolate was used. The calves were allocated by restricted randomization based on body weight within sex to one of the following treatments: unmedicated control with no rain, Ivomec Pour-On with no rain, Ivomec Pour-On with rain starting at 40 min before treatment, Ivomec Pour-On with rain starting at 10 min after treatment, and Ivomec Pour-On with rain starting at 60 min after treatment. Ivomec Pour-On was applied topically at a dose rate of 1 ml/10 kg body weight (500 microg ivermectin/kg body weight). The simulated rainfall was equivalent to a heavy shower of approximately 12.5 mm of water during a 30-min period. The calves were necropsied for worm counting at 14 or 15 days after treatment. An evaluation of the pooled data showed that as compared with the untreated controls, the Ivomec Pour-On-treated calves with no rain had significantly (P < 0.01) fewer C. oncophora (> 99%), C. punctata (> 99%), C. surnabada (> 98%), and combined Cooperia spp. (> 99%). The reduction in Cooperia numbers noted for calves exposed to simulated rainfall was > 96% for all Cooperia species, regardless of when the rainfall started relative to the application of Ivomec Pour-On. There was no significant (P > 0.1) difference between the Ivomec Pour-On-treated calves with no rain and the pooled groups with simulated rainfall or between the group with rain before treatment and the pooled groups with rain after treatment. Ivomec Pour-On was highly effective against established infections of Cooperia spp. when applied to wet animals or to animals becoming wet shortly after treatment.

Efficacy of ivermectin in a controlled release formulation against Psoroptes ovis (Hering, 1838) gervais, 1841 (Acari: Psoroptidae) on sheep.

Three trials including 42 sheep were conducted in Brazil or Germany to evaluate the therapeutic (two trials) and prophylactic (one trial) efficacy of an ivermectin controlled release capsule (CRC) against Psoroptes ovis infestation. In one therapeutic trial naturally infested sheep were used while in the other trials infestations were experimentally induced. In each trial half of the animals were treated on Day 0 with one ivermectin controlled release capsule that delivers ivermectin at a rate of 1.6 mg/day for approximately 100 days, that is 20 mcg/kg/day to a 80 kg animal, while the other half remained untreated. In both therapeutic trials mites were counted in skin scrapings and their presence was recorded at predilection sites one day before treatment and at weekly intervals from Day 7 to Day 56. In the trial conducted to evaluate the prophylactic efficacy the sheep were experimentally infested with P. ovis 21 and 28 days post-treatment and mites were counted and recorded at predilection sites on Days 42, 49 and 56. The ivermectin controlled release capsule was completely effective in eliminating the P. ovis mites within 28 days of administration and it prevented the establishment of an infestation of P. ovis induced 21 and 28 days after administration.

Efficacy of ivermectin in a controlled-release capsule for the control of breech strike in sheep.

OBJECTIVE: To investigate the efficacy of ivermectin in an intraruminal controlled-release capsule (CRC) against blowfly strike. DESIGN: Pen and field trials with controls. ANIMALS: Pen studies: Two breech strike trials involving 60 Romney and 60 Merino sheep. One body strike trial using 100 Merino sheep. Field trials: Eight trials in New Zealand used 1000 Romney and Romney-cross sheep. Fifty Merino lambs in one trial in Australia. PROCEDURE: Pen studies: Sheep were allocated to two equal groups. One was not treated, the other sheep received a CRC that delivered ivermectin at > or = 20 micrograms/kg/day for 100 days. In the breech strike trials, each animal was given an oral laxative 2 days before exposure to adult Lucilia cuprina. In the body-strike trial, the sheep sheep were kept wet to increase susceptibility prior to the release of blowflies. Field trials: Fifty or 200 sheep allocated to equal groups of nontreated or treated with the CRC and grazed at pasture exposed to natural blowfly challenge. RESULTS: Pen studies: Breech strikes developed in 24 of 60 controls but in none of 60 CRC-treated sheep. There was a 35% reduction in the number of CRC-treated sheep struck on the body. Field trials: The average number of breech strikes in CRC-treated sheep was reduced by 86% (P < 0.001). The number of body strikes in the treated groups was a reduced by 27% (P < 0.05). CONCLUSION: The ivermectin CRC is a useful aid in controlling breech strike, but provides only moderate reduction in the incidence of body strike.

Efficacy of an ivermectin controlled-release capsule against nematode and arthropod endoparasites in sheep.

Five controlled trials were conducted in Germany or in the United Kingdom, using 74 female sheep of merino or Dorset horn breeds, to evaluate the efficacy of an ivermectin controlled-release capsule against naturally acquired or induced infections of gastrointestinal nematodes, lungworms and nasal bot larvae and against incoming infections with gastrointestinal and pulmonary nematodes. Half of the animals were treated with one ivermectin controlled-release capsule that delivered ivermectin at the rate of 1.6 mg per day for 100 days while the other half remained untreated. Parasites were counted 21, 28, 35 or 56 days after administration of the capsule. The treatment was highly effective (> or = 99 per cent) against established parasites of the following species: Haemonchus contortus (adults and fourth-stage larvae), Ostertagia circumcincta, O pinnata, O trifurcata, Ostertagia species fourth-stage larvae, Trichostrongylus axei, T colubriformis, T vitrinus, Cooperia curticei, Nematodirus battus, N filicollis, Strongyloides papillosus, Chabertia ovina, Oesophagostomum venulosum, Trichuris ovis, Tr skrjabini, Dictyocaulus filaria, Protostrongylus rufescens and Oestrus ovis (larvae). The treatment prevented the establishment of the gastrointestinal nematodes H contortus, O circumcincta, T axei, T colubriformis, C curticei, N battus, N filicollis, Ch ovina, Oe vennulosum and the establishment of the lungworm D filaria by > 99 per cent compared with untreated controls (P < or = 0.01).

Field trials evaluating ivermectin controlled-release capsules for weaner sheep and for breeding ewes.

OBJECTIVE: To confirm the efficacy of ivermectin released from a controlled-release capsule administered to young sheep and to breeding ewes under field conditions. DESIGN: Randomised field trials. PROCEDURE: In each of ten field trials 25 weaned lambs were treated with ivermectin controlled-release capsules and 25 remained untreated. Eight similar field trials were conducted using adult ewes. Efficacy against infections of gastrointestinal nematodes was assessed by faecal egg counts and faecal larval culture. Body weights were recorded and faecal soiling of the breech wool (dags) was assessed. RESULTS: Nematode faecal egg counts in the two groups were not different (P = 0.13) before treatment in the weaner trials or before treatment in the ewe trials (P = 0.49), but thereafter eggs in the untreated sheep persisted, whereas counts in sheep given capsules were negligible (P < or = 0.01). In the weaner trials, dag scores for the two groups were not different at the start of the trials (P = 0.18) but at the end, untreated sheep had significantly more dags (P = 0.04) than treated sheep. In the ewe trials, dag scores remained low in both groups. Weaners treated with the capsule gained 1.4 kg (95% CL: 0.7, 3.1) more weight over the 16 week trial period compared to untreated weaners (P = 0.01). Both groups of ewes lost weight as a result of parturition but the mean loss by week 16 was greater for untreated (3.7 kg) (95% CL: -5.1, -2.2) than for treated ewes (1.8 kg) (95% CL: -3.3, -0.4). The mean change in ewe body weight for the two groups was however not significant (P = 0.07). Differentiation of nematode larvae recovered from cultures of faeces from untreated animals indicated that the capsules were effective against the common parasites of sheep. CONCLUSION: The capsule was efficacious against gastrointestinal nematodes judging from faecal egg counts. It has the potential to significantly reduce contamination of pasture with nematode eggs. Treated weaners had less dags for 16 weeks and gained more weight than untreated weaners.

Efficacy of an in-feed formulation of ivermectin against somatic larvae of Strongyloides ransomi in pregnant swine.

OBJECTIVE: To confirm that ivermectin fed for 7 days to pregnant sows controls transmission of Strongyloides ransomi larvae to pigs via the colostrum or milk. ANIMALS: 24 mixed-breed sows. PROCEDURE: The sows were infected with 250,000 S ransomi larvae on 3 occasions (days 63, 64, or 65, days 71 or 73, and days 78, 79, or 80 of gestation). Eight sows received ivermectin at a dosage of 100 micrograms of ivermectin/kg of body weight/d from days 92 to 99 of gestation, and 8 sows were treated from days 103 to 110 of gestation; 8 remaining sows received unmedicated vehicle. Numbers of S ransomi larvae were counted in samples of colostrum or milk collected 1, 2, and 7 days after parturition. At 7 and 14 days after parturition, fecal samples were collected from each sow and from 4 pigs from each litter for determination of nematode egg counts; at the latter date, pigs were euthanatized and necropsied for worm counting. RESULTS: Pigs born to ivermectin-treated sows had significantly (P < 0.01) fewer adult S ransomi than did those born to control sows; efficacy was 100%. Treated sows had significantly (P < 0.05) fewer S ransomi larvae in colostrum/milk samples taken 1, 2, and 7 days after parturition than did control sows; efficacy was 100%, with the exception of 1 S ransomi larva found in a milk sample from 1 treated sow at 2 days after parturition. CONCLUSION AND CLINICAL RELEVANCE: Ivermectin fed to sows during the last third of gestation at a dosage of 100 micrograms/kg/d for 7 consecutive days is highly efficacious for control of transmission of infective S ransomi larvae to pigs via colostrum or milk.

Efficacy of eprinomectin against Hypoderma spp in cattle.

OBJECTIVE: To determine the efficacy of a topical formulation of eprinomectin against natural infestations of first (L1)-stage, and second and third (L2/L3)-stage larvae of Hypoderma spp. ANIMALS: 140 approximately 6- to 18-month-old cattle of various breeds. PROCEDURE: Cattle, selected from herds with high prevalence of Hypoderma infestation, were treated in 4 experiments: within each replicate, 1 animal received eprinomectin at a dosage of 500 micrograms/kg of body weight against first-stage larvae (L1). The second animal received the same treatment against second or third-stage larvae (L2/L3). The third animal served as an untreated control. In a fifth experiment, visible warbles were treated on half of the cattle. Remaining cattle served as vehicle-treated controls. In 1 experiment, warbles were examined from time of treatment until all lesions were resolved. In 4 experiments, emerging Hypoderma larvae were recovered, speciated, and enumerated, and viability was determined. RESULTS: Eprinomectin (500 micrograms/kg) efficacy was complete against L1. Hypoderma L2/L3 eradication approached 100% efficacy (1 live larva was recorded). Warbles in treated cattle resolved in a significantly shorter time than did those in controls. Adverse reactions related to treatment were not observed in any of the trials. CONCLUSIONS: Eprinomectin (500 micrograms/kg) applied topically was safe and highly efficacious for treatment of all larval stages of Hypoderma spp in these trials. CLINICAL RELEVANCE: Attributes of eprinomectin besides antiparasite efficacy allow treatment of all classes of cattle with no need for meat or milk withdrawal.

Prophylactic use of ivermectin against cattle myiasis caused by Cochliomyia hominivorax (Coquerel, 1858).

The prophylactic efficacy of ivermectin against navel or scrotal myiasis in calves was evaluated in eight trials in Argentina and Brazil. In two trials, calves were injected subcutaneously with ivermectin at a dosage of at least 200 microg kg(-1) within 24 h of birth. In the other six trials, two with two-month-old calves and four with four-month-old or older calves, all calves were treated with ivermectin at a dosage of at least 200 microg kg(-1) immediately after castration. In all trials, calves were maintained together on pasture and naturally exposed to Cochliomyia hominivorax. Navel and scrotal wounds were examined for myiasis daily for at least 14 days. Incidence of navel and scrotal myiasis was significantly lower (P < 0.01) in treated calves than in control calves.

Demonstration of the sustained anthelmintic efficacy of a controlled-release capsule formulation of ivermectin in weaner lambs under field conditions in New Zealand.

Ten field trials were conducted in the North and South Islands of New Zealand to evaluate the anthelmintic efficacy and production responses attributable to treatment of weaner lambs with an intra-ruminal controlled-release capsule formulation of ivermectin. A total of 800 Coopworth, Perendale and Romney lambs weighing on average 20.8-34.8 kg were used. Lambs were either untreated or treated shortly after weaning with an ivermectin controlled-release capsule which delivers ivermectin at 0.8 mg per day for 100 days (minimum dose rate 20 microg/kg/day). Bodyweights, faecal nematode egg counts and dag scores (assessment of faecal soiling in the breech area) were determined before treatment and at about 4,8, 12, 14 and 16 weeks after treatment. Sheep treated with the Ivermectin capsule gained significantly more weight (11.6 kg) over the 16 weeks of the trials compared to untreated sheep (7.3 kg) (p < 0.01). Before treatment, faecal strongylid and Nematodirus spp. egg counts were equivalent (p > 0.10) but, at each time point thereafter, egg counts in ivermectin capsule-treated sheep were significantly lower (p < 0.01 or p < 0.05). Dag scores were not different at the start of the trial (p > 0.10), but at the end of the trial control sheep had significantly greater dags (p < 0.05) than sheep treated with the ivermectin capsule. These findings indicate that treated animals contributed significantly fewer nematode eggs to the contamination of pasture and therefore pasture contamination should be significantly reduced for at least 112 days. The productivity of the ivermectin capsule-treated sheep over the I6 weeks of the trials was also significantly increased compared to salvage-treated controls. Furthermore, the presence of dags, which predispose sheep to blowfly strike in the breech area and result in production losses due to the costs of dagging and downgrading of breech wool, were also significantly (p < 0.05) reduced in the ivermectin capsule-treated sheep.

Demonstration of the sustained anthelmintic activity of a controlled-release capsule formulation of ivermectin in ewes under field conditions in New Zealand.

Ten field trials were conducted in the North and South Islands of New Zealand to evaluate the anthelmintic efficacy of an intraruminal controlled-release capsule formulation of ivermectin. A total of 810 Coopworth, Perendale, Romney or Coopworth ' Romney ewes, weighing on average 42-70 kg, were used. Ewes were either untreated or treated shortly before lambing in late winter-early spring (eight trials) or in late spring (two trials) with an ivermectin controlled-release capsule which delivers ivermectin at 1.6 mg per day for 100 days (minimum dose rate 20microg/kg/day). Bodyweights, faecal nematode egg counts and dag scores were determined before treatment and at about 2 and/or 4, 6 or 8, 10 or 12, 14 and 16 weeks after treatment. Ewes treated with the ivermectin controlled-release capsule gained on average 1.1kg more than untreated sheep over the 16 weeks of the trials, but this difference was not significant (p > 0.10). Before treatment, faecal strongylid egg counts were equivalent (p > 0.10), but at each time point thereafter, egg counts in ivermectin controlled-release capsule treated sheep were significantly lower (p < 0.01; p < 0.05 at Week 2). Dag scores were not different at the start of the trial (p > 0.10), but at the end of the trial ivermectin controlled-release capsule treated ewes had significantly lower scores (p < 0.01) than untreated ewes. These findings indicated that treated animals shed significantly fewer nematode eggs and therefore pasture contamination with nematode eggs should be significantly reduced for at least 112 days. The control of dags should result in reduced direct losses due to the decreased value of dag wool, and indirect losses due to the cost of dagging sheep and the cost associated with the treatment and control of flystrike initiated by dags in the breech area.

Control of gastro-intestinal parasitism in sheep with ivermectin delivered via an intraruminal controlled-release capsule.

The efficacy of ivermectin delivered by an intraruminal controlled-release capsule against gastro-intestinal nematodes of sheep was evaluated under controlled conditions. In seven Australian studies involving 170 Merino or Merino x Border Leicester sheep, intraruminal capsules developed for 20-40 kg or 40-80 kg sheep, and delivering 0.8 or 1.6 mg of ivermectin/day respectively for 100 days (minimum dose 20 microg/kg/day), were evaluated. Studies were designed to test the therapeutic efficacy against naturally acquired and induced infections treated at the adult and fourth larval stage, and the prophylactic efficacy against naturally acquired and induced infections with third stage infective larvae. The predominant pathogenic nematodes of sheep were represented. Two studies included known benzimidazole- and levamisole-resistant nematode strains. Sheep were necropsied for total nematode counts 21-8.5 days after treatment. The efficacy of the ivermectin controlled-release capsule was generally >99% against all nematode species tested, including those confirmed to be benzimidazole- and levamisole-resistant. High therapeutic activity was demonstrated against existing adult and fourth larval stage nematode infections at the time of treatment, and high prophylactic efficacy was shown against incoming third stage larvae of all species and strains tested.

Efficacy of ivermectin controlled-release capsules for the control and prevention of nasal bot infestations in sheep.

OBJECTIVE: To investigate the therapeutic and prophylactic efficacy of an ivermectin controlled-release capsule against nasal bots (Oestrus ovis) in sheep. DESIGN: Trial 1--A pen study with controls. Trial 2--A field study with controls. ANIMALS: Trial 1--Forty Merino wethers with natural infestations of nasal bot were used. Trial 2--One hundred nasal bot-free wethers were used. PROCEDURE: Trial 1--Ten randomly selected animals were slaughtered and the heads split and examined to confirm bot infestation. Fifteen animals were allocated to untreated controls and 15 to treatment with a controlled-release capsule delivering ivermectin at > or = 20 micrograms/kg/day for 100 days. Twenty-nine days after treatment the sheep were killed and examined for nasal bots. Trial 2--Nasal bot-free sheep were allocated to two groups of 45 animals. One group was untreated the other sheep were treated with capsules as above. The sheep were grazed as a single group exposed to natural challenge from O ovis. Ninety days after treatment the animals were slaughtered and examined for nasal bot infestation. RESULTS: Trial 1--Live O ovis larvae were recovered from 60% of control sheep. No live larvae were collected from treated sheep. Trial 2--Forty-one percent of untreated sheep harbored nasal bot infestations. No live larvae were collected from any treated animal. CONCLUSION: Treatment with a single ivermectin controlled release capsule was 100% effective against existing infestations of O ovis and as a prophylactic treatment for this parasite.

Eprinomectin: a novel avermectin for control of lice in all classes of cattle.

Eight trials were conducted in the United States to determine the efficacy of eprinomectin applied topically against four common species of lice in cattle. In two dose titration trials, eprinomectin dosages of 125 to 750 mcg/kg body weight applied topically were compared to untreated controls. In dose confirmation studies, animals treated topically with eprinomectin applied at the rate of 500 mcg/kg were compared to vehicle-treated controls. Four species of lice were present in these trials: Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus, all sucking lice, and Damalinia (Bovicola) bovis, the cattle biting louse. Louse counts were made on six to nine predilection sites (the same number of sites in all animals in the same trial) prior to treatment. The same sites were counted again seven days after treatment and weekly thereafter until trial termination eight weeks after treatment. When no lice were found in the predilection sites, a modified whole body search was conducted. Each species of lice was present on at least six animals in each treatment group on at least one counting date in two or more trials. No lice were found on any animal treated topically with eprinomectin at a dosage of > or = 500 mcg/kg after 14 days posttreatment until termination of the trials eight weeks after treatment.

Efficacy of an in-feed formulation of ivermectin against adult worms and somatic larvae of Strongyloides ransomi.

The efficacy of an in-feed formulation (IVOMEC premix) containing 0.6% ivermectin was tested against Strongyloides ransomi in swine. The efficacy of ivermectin against patent infections of S. ransomi when given via the feed at 2 ppm for 7 days (Days 0-7) to provide 100 mcg ivermectin kg-1 body weight day-1 was evaluated in a study with 16 3-month-old male castrated piglets. Seven days prior to treatment each piglet was infected subcutaneously with 2500 infective larvae of S. ransomi. Fecal egg counts were carried out on Days -7, 0, 7 and 14, and worm counts on Day 14. Efficacy was 100% in all treated piglets. Two trials involving 40 pregnant gilts were carried out to evaluate the efficacy of ivermectin against the somatic larval stages of S. ransomi when given at a daily dose of 100 mcg kg-1 body weight for 7 days starting on Days 66, 78, 92 or 103 of pregnancy. The gilts were each experimentally infected with three subcutaneous injections of 250,000 infective larvae, with the last infection given between 12 and 30 days prior to commencement of treatment. Gilts were confirmed free of pre-existing intestinal stages of S. ransomi prior to ivermectin treatment. Fecal nematode egg counts were carried out in gilts/sows and piglets subsequently born. The Strongyloides larvae present in sow milk 1, 2 and 7 days post partum were counted. Fourteen days post natum, worm counts were performed in four randomly selected piglets for each litter. IVOMEC premix given to pregnant gilts prevented shedding of larvae in sow milk, egg output in feces and the establishment of S. ransomi in piglets.

Rainfall and breed effects on the efficacy of ivermectin jetting fluid for the prevention of fly strike and treatment of infestations of lice in long-wooled sheep.

An ivermectin-based jetting fluid was assessed for its efficacy in the prevention of blowfly strike and treatment of lice in long-wooled sheep. The ivermectin concentrate was diluted to 0.03 mg/mL and applied via a standard hand jetting technique. In insectary studies, using laboratory-reared Lucilia cuprina, sheep jetted with ivermectin were protected from induced breech and body strikes for 18 weeks after treatment. Merino and Corriedale sheep were equally protected, as were sheep subjected to 25 mm simulated rainfall at 1, 3 or 6 hours after jetting. Naturally occurring infestations of lice, Bovicola (Damalinia) ovis, were successfully treated with ivermectin jetting fluid in Merino and Corriedale sheep using a standard hand jetting technique. In addition, the efficacy of treatment was not affected by simulated rainfall at 1, 3 or 6 hours after treatment.

Efficacy of ivermectin jetting fluid for the curative treatment of blowfly strikes in sheep.

A jetting fluid containing 7.5% w/v ivermectin, which was diluted to 0.03 mg/mL in water and applied using a standard hand jetting technique, was assessed for its efficacy in treating blowfly strikes on Merino sheep. Strikes were induced on sheep held under insectary conditions using laboratory-reared Lucilia cuprina. All struck sheep jetted at 28, 48 or 72 hours after exposure to flies were successfully treated. All 1st, 2nd and early 3rd instar larvae were killed within 24 hours of treatment.

The efficacy of ivermectin jetting fluid for control of blowfly strike on sheep under field conditions.

Seventeen trials involving 5737 sheep were conducted to test the efficacy of ivermectin jetting fluid (30 ppm in water) for the control of blowfly strike when applied to sheep either by standard hand jetting or through an automatic jetting race. Sheep were observed for up to 14 weeks after treatment and all strikes recorded. The level of fly challenge varied between trials, resulting in strike rates in untreated sheep ranging between 0 and 94%. At 12 weeks after treatment there were 93% fewer strikes in hand jetted sheep and 84% fewer strikes in machine jetted sheep when compared with untreated sheep. At this time and point there was a 90%, 86% and 93% reduction in poll, body and breech strikes, respectively, when hand jetting was used, whereas machine jetting reduced poll, body, breech and pizzle strikes by 84%, 81%, 79% and 100%, respectively.

Field trials to confirm the efficacy of ivermectin jetting fluid for control of blow fly strike in sheep.

Fifty-two field trials, involving 14,296 sheep, were conducted to confirm the efficacy and safety of ivermectin jetting fluid against blow fly strike in sheep in Australia. A total of 7143 sheep were treated by hand-jetting with a 0.03 mg ml-1 solution of ivermectin, while 7153 sheep were untreated controls. The percent reduction in the cumulative incidence of strikes within the treatment area for ivermectin-treated sheep in comparison with untreated controls, was 96.5%, 95.8% and 93.5% at 10, 12 and 13/14 weeks after treatment, respectively. There were no adverse reactions to treatment.